Key clinical point: Denosumab raised spinal bone mineral density (BMD) significantly more than did oral alendronate.
Major finding: Lumbar spine BMD increased 3.5% with denosumab versus 2.5% with alendronate.
Study details: A 12-month study of 69 patients randomly assigned to denosumab and another 70 to alendronate.
Disclosures: The trial was an investigator-initiated study. Dr. Mok and colleagues had no relevant financial disclosures.
Mok CC et al. Arthritis Rheumatol. 2020;72(suppl 10). ACR 2020, Abstract 1442.